Episode

Episode 76: Evolocumab's Impact on Coronary Physiology and Microstructure in De Novo Heart Transplant Recipients

Podcast
JHLT: The Podcast
Published
Jan 21, 2026
Duration seconds
1164
Processing state
not_requested
Canonical source
https://thejhlt.libsyn.com/episode-76-evolocumabs-impact-on-coronary-physiology-and-microstructure-in-de-novo-heart-transplant-recipients
Audio
https://traffic.libsyn.com/secure/thejhlt/JHLT_jan_2026_pt_2.mp3?dest-id=2489450
JSON
/v1/public/podcasts/jhlt-the-podcast-3498579/episodes/episode-76-evolocumab-s-impact-on-coronary-physiology-and-microstructure-in-de-novo-heart-transplant-recipients
Markdown
/podcast/jhlt-the-podcast-3498579/episode-76-evolocumab-s-impact-on-coronary-physiology-and-microstructure-in-de-novo-heart-transplant-recipients.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/jhlt-the-podcast-3498579/episodes/episode-76-evolocumab-s-impact-on-coronary-physiology-and-microstructure-in-de-novo-heart-transplant-recipients/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/jhlt-the-podcast-3498579/episode-76-evolocumab-s-impact-on-coronary-physiology-and-microstructure-in-de-novo-heart-transplant-recipients.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

JHLT: The Podcast returns with an episode discussing the paper, " Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients ," from the January issue of JHLT . Featured on this episode is early career guest host Bin Yang, MD , of Massachusetts General Hospital. Mentored by Digital Media Editor Van-Khue Ton, MD, PhD , Dr. Yang shares hosting duties this episode and brings great questions to the discussion. Drs. Yang and Ton are joined by the first author, Salma Karim , and senior author, Hans Eiskjaer , both from Aarhus University Hospital in Denmark. The discussion explores: What imaging and physical markers the researchers used to determine if evolocumab was influencing the development of cardiac allograft vasculopathy (CAV) The potential role of lipid-lowering therapies or statins in treating CAV The relationship between CAV and microvascular resistance (IMR) For the latest studies from JHLT , visit www.jhltonline.org/current , or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt . In case you missed it, earlier this month the JHLT Digital Media Editors recapped their favorite papers from 2025. Take a listen! Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org .